| [1] |
Siegel RL, Miller KD. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. doi:10.3322/caac.21551URL |
| [2] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. doi:10.3322/caac.21338URL |
| [3] |
Pierrou S, Hellqvist M, Samuelsson L, et al. Cloning and characterization of seven human forkhead proteins: bin-ding site specificity and DNA bending[J]. EMBO J, 1994, 13(20):5002-5012. doi:10.1002/j.1460-2075.1994.tb06827.xpmid:7957066 |
| [4] |
Nakayama S, Soejima K, Yasuda H, et al. FOXD1 expression is associated with poor prognosis in non-small cell lung cancer[J]. Anticancer Res, 2015, 35(1):261-268. pmid:25550559 |
| [5] |
Zhao YF, Zhao JY, Yue H, et al. FOXD1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27[J]. Biochem Biophys Res Commun, 2015, 456(1):232-237. doi:10.1016/j.bbrc.2014.11.064URL |
| [6] |
Li D, Fan S, Yu F, et al. FOXD1 promotes cell growth and metastasis by activation of vimentin in NSCLC[J]. Cell Physiol Biochem, 2018, 51(6):2716-2731. doi:10.1159/000495962URL |
| [7] |
Farhan M, Wang H, Gaur U, et al. FOXO signaling pathways as therapeutic targets in cancer[J]. Int J Biol Sci, 2017, 13(7):815-827. doi:10.7150/ijbs.20052pmid:28808415 |
| [8] |
Ernstsson S, Pierrou S, Hulander M, et al. Characterization of the human forkhead gene FREAC-4. Evidence for regulation by Wilms' tumor suppressor gene (WT-1) and p53[J]. J Biol Chem, 1996, 271(35):21094-21099. doi:10.1074/jbc.271.35.21094pmid:8702877 |
| [9] |
Gao YF, Liu JY, Mao XY, et al. LncRNA FOXD1-AS1 acts as a potential oncogenic biomarker in glioma[J]. CNS Neurosci Ther, 2020, 26(1):66-75. doi:10.1111/cns.13152URL |
| [10] |
Song R, Lopez M, Yosypiv IV. Foxd1 is an upstream re-gulator of the renin-angiotensin system during metanephric kidney development[J]. Pediatr Res, 2017, 82(5):855-862. doi:10.1038/pr.2017.157URL |
| [11] |
Wu Q, Ma J, Wei J, et al. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway[J]. Mol Oncol, 2020-05-27.[online ahead of print]. |
| [12] |
Wang Y, Qiu C, Lu N, et al. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner[J]. Int J Oncol, 2018, 52(6):2130-2142. doi:10.3892/ijo.2018.4359pmid:29620165 |
| [13] |
Pan F, Li M, Chen W. FOXD1 predicts prognosis of co-lorectal cancer patients and promotes colorectal cancer progression via the ERK 1/2 pathway[J]. Am J Transl Res, 2018, 10(5):1522-1530. |
| [14] |
Li CH, Chang YC, Hsiao M, et al. FOXD1 and Gal-3 form a positive regulatory loop to regulate lung cancer aggressiveness[J]. Cancers (Basel), 2019, 11(12):1897-1915. doi:10.3390/cancers11121897URL |
| [15] |
Gao YF, Zhu T, Mao XY, et al. Silencing of forkhead box D1 inhibits proliferation and migration in glioma cells[J]. Oncol Rep, 2017, 37(2):1196-1202. doi:10.3892/or.2017.5344URL |
| [16] |
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition[J]. Nat Rev Mol Cell Biol, 2014, 15(3):178-196. doi:10.1038/nrm3758URL |
| [17] |
Li X, Dong M, Zhou J, et al. C6orf106 accelerates pancreatic cancer cell invasion and proliferation via activa-ting ERK signaling pathway[J]. Mol Cell Biochem, 2019, 454(1-2):87-95. doi:10.1007/s11010-018-3455-0URL |
| [18] |
Qi ZH, Xu HX, Zhang SR, et al. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling[J]. Int J Oncol, 2018, 52(4):1105-1116. |